New Website for Cancer Pain Patients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 5
Volume 10
Issue 5

NEW YORK-The Association of Cancer Online Resources (ACOR) has launched a new website, Cancer-pain.org, to provide cancer patients with the education and support they need to obtain effective pain relief.

NEW YORK—The Association of Cancer Online Resources (ACOR) has launched a new website, Cancer-pain.org, to provide cancer patients with the education and support they need to obtain effective pain relief.

The site features sections on the causes of pain, breakthrough pain, pain treatment options, and tools to help cancer patients communicate effectively with physicians about their pain. It also has a complete list of medications available to treat pain, information about complementary and alternative methods of pain control, and a section devoted to the special needs and issues of caregivers. The website is supported through an educational grant from Cephalon, Inc.

Articles in this issue
Adjuvant Chemo Dose Reductions Frequent in Breast Cancer
Women May Be at Greater Risk for Undertreatment of Cancer Pain
Umbilical Cord Blood in Adult Leukemia Patients
Irinotecan Results Continue to Be Encouraging in Colorectal Cancer
Irinotecan Active in Pediatric Cancers
Combined Modality Therapy Has Enhanced Activity in Locally Advanced Rectal Cancer
Ultrasound Contrast Agents Help Diagnose Prostate Cancer
Optimal Use of Irinotecan Still to be Determined
Groups Urge Federal Action Against Eclipse Cigarettes
Potential Advantages of Oral Irinotecan Defined in Phase I Studies
New Website for Cancer Pain Patients
Creative Center for Women With Cancer Adds the Performing Arts
More Precise Surrogate Markers for Clinical Response Are Needed
Rubitecan Appears Active in Advanced Pancreatic Cancer
Physicians Must Unite Against New Bureaucratic ‘Hassles’ to Practicing Medicine
Recent Videos
Focused, high-dose radiotherapy doses may prolong survival and the interval to subsequent therapy for patients with advanced prostate cancer.
Data show increasing use of proton therapy overall but widening gaps in populations who have access to this treatment, says Curtiland Deville Jr., MD.
2 experts are featured in this series.
Related Content
103 Leveraging Digital Technology to Improve Breast Cancer Patients’ Understanding of Treatment Recommendations

103 Leveraging Digital Technology to Improve Breast Cancer Patients’ Understanding of Treatment Recommendations

Caroline Welsh;Nicole Taylor;Julie Cole;Manjeet Chadha
April 8th 2025
Article
Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care Via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

The phase 3 MIRAGE trial findings show that PROSTOX ultra was validated as a biomarker to predict genitourinary toxicity following SBRT.

PROSTOX Ultra Reliably Predicts Long-Term Radiation AEs in Prostate Cancer

Roman Fabbricatore
April 8th 2025
Article

The phase 3 MIRAGE trial findings show that PROSTOX ultra was validated as a biomarker to predict genitourinary toxicity following SBRT.

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
April 1st 2025
Podcast

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

FDA Approves Nivolumab/Ipilimumab in Adult/Pediatric MSI-H or dMMR CRC

FDA Approves Nivolumab/Ipilimumab in Adult/Pediatric MSI-H or dMMR CRC

Tim Cortese
April 8th 2025
Article

The FDA approved nivolumab with ipilimumab in adult and pediatric patients with CRC based on data from the phase 3 CHECKMATE-8HW trial.

PENELOPE-B Trial Shows Mixed Palbociclib Results in Breast Cancer Subtypes

PENELOPE-B Trial Shows Mixed Palbociclib Results in Breast Cancer Subtypes

Tim Cortese
April 8th 2025
Article

Palbociclib with endocrine therapy did not improve outcomes in HR-positive, HER2-negative breast cancer, but improved invasive DFS in lobular disease.